Ovarian cancer: trials for referral
886 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 886 open trials.
Phase 123 sites
Not yet recruitingSpain, France, United Kingdom, Japan, United States
NCT07928258
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
Eli Lilly and Company
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 1/241 sites
RecruitingAustralia, Canada, Switzerland, Spain, United Kingdom, Israel
NCT06843447
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Merck Sharp & Dohme LLC
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 125 sites
RecruitingSpain, France, United Kingdom, United States
NCT06515613
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics Inc.
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 127 sites
RecruitingSpain, Georgia, United States
NCT07503808
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 3205 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, Canada
NCT06824467
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Merck Sharp & Dohme LLC
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 3192 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, Canada
NCT07318558
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Merck Sharp & Dohme LLC
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 37 sites
RecruitingIsrael, Taiwan, United States
NCT07743164
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Merck Sharp & Dohme LLC
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 110 sites
RecruitingUnited Kingdom
NCT07665515
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Epitopea Ltd
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07718854
Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
Tufts Medical Center
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 40 sites
Not yet recruiting
NCT07469202
CYTALUX Dose Extension Study
On Target Laboratories, LLC
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT01174121
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 223 sites
RecruitingUnited States
NCT07504588
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT04847063
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 3709 sites
RecruitingJapan, Puerto Rico, United States
NCT06580314
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07905677
Phase 1 Study of VT-101 in Advanced Ovarian Cancer
Michael J. Goodheart
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 3129 sites
RecruitingArgentina, Australia, Belgium, Brazil, Canada, Germany
NCT07546500
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 30 sites
Not yet recruiting
NCT07926048
A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Qilu Pharmaceutical Co., Ltd.
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 135 sites
RecruitingAustralia, Bosnia and Herzegovina, Bulgaria, France, Georgia, South Korea
NCT04516447
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingBelgium
NCT07902375
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Universiteit Antwerpen
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 3173 sites
RecruitingArgentina, Australia, Bulgaria, Brazil, Canada, Chile
NCT07851025
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
AstraZeneca
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 14 sites
RecruitingChina
NCT07923214
A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 256 sites
RecruitingCanada, South Korea, Türkiye, Taiwan, United States
NCT06787612
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govNo phase46 sites
RecruitingUnited States
NCT06995898
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 121 sites
RecruitingSouth Korea, United States
NCT06586957
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 26 sites
RecruitingCanada, United States
NCT04918186
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Canadian Cancer Trials Group
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 313 sites
RecruitingUnited Kingdom, Israel, South Korea, Taiwan, United States
NCT07776691
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Merck Sharp & Dohme LLC
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06885697
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07920159
Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian Cancer
Anhui Provincial Hospital
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07919509
A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical Procedures
University of Alabama at Birmingham
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 242 sites
RecruitingSpain, Georgia, South Korea, United States
NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States232 open trials
- China92 open trials
- Spain74 open trials
- France59 open trials
- Australia56 open trials
- United Kingdom51 open trials
- South Korea49 open trials
- Japan47 open trials
- Italy41 open trials
- Germany35 open trials
- Belgium33 open trials
- Canada31 open trials
- Taiwan23 open trials
- Israel19 open trials
- Poland19 open trials
- Netherlands17 open trials
- Denmark16 open trials
- Brazil13 open trials
- Czechia12 open trials
- Switzerland11 open trials
- Ireland11 open trials
- Puerto Rico10 open trials
- Austria8 open trials
- Hungary8 open trials
- Argentina7 open trials
- Greece7 open trials
- Sweden7 open trials
- Thailand6 open trials
- Portugal6 open trials
- Georgia5 open trials
- Finland5 open trials
- India5 open trials
- Türkiye5 open trials
- Singapore5 open trials
- Mexico4 open trials
- Norway4 open trials
- Chile3 open trials
- Romania3 open trials
- Bulgaria3 open trials
- Peru2 open trials
- Ukraine2 open trials
- Colombia1 open trial
- Croatia1 open trial
- Bosnia and Herzegovina1 open trial
- Serbia1 open trial
- Philippines1 open trial
- Estonia1 open trial
- Slovenia1 open trial
- Malaysia1 open trial
- Slovakia1 open trial
- Uruguay1 open trial
- Lithuania1 open trial
- Russia1 open trial
- New Caledonia1 open trial
- Réunion1 open trial
- Guadeloupe1 open trial
- Martinique1 open trial
- Saudi Arabia1 open trial
- New Zealand1 open trial
- Nigeria1 open trial
- Belarus1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, China
16 trials · 37 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
New in the registry
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
NCT07928258 · Phase 1 · Spain, France, United Kingdom, Japan, United States
Source: ClinicalTrials.govClosed for recruitment
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NCT05652283 · Phase 2 · China
Source: ClinicalTrials.govOpened for recruitment
Phase 1 Study of VT-101 in Advanced Ovarian Cancer
NCT07905677 · Phase 1 · United States
Source: ClinicalTrials.govNew in the registry
A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT07923214 · Phase 1 · China
Source: ClinicalTrials.govNew in the registry
Study of Suvemcitug Plus Chemotherapy in Advanced High-Grade Serous Ovarian Cancer
NCT07920159 · Phase 2
Source: ClinicalTrials.govStopped early
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06756035 · Phase 1 · United States
Source: ClinicalTrials.govOpened for recruitment
NCT07736937 · Phase 1/2 · Belgium, Ukraine, United States
Source: ClinicalTrials.govOpened for recruitment
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089 · Phase 2 · Australia, China, Germany, Spain, France, Italy
Source: ClinicalTrials.govClosed for recruitment
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185 · Phase 1 · Belgium, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govOpened for recruitment
NCT06476808 · Phase 1 · Canada, Spain, France, Italy, United States
Source: ClinicalTrials.govOpened for recruitment
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613 · Phase 1 · Spain, France, United Kingdom, United States
Source: ClinicalTrials.govOpened for recruitment
NCT06161025 · Phase 2/3 · Australia, Brazil, Canada, China, Czechia, Germany
Source: ClinicalTrials.gov
Show more
Closed for recruitment
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231 · Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govPhase changed: Phase 1 → Phase 1/2
NCT05797168 · Phase 1/2 · Australia, Canada, China, Germany, Spain, United Kingdom
Source: ClinicalTrials.govOpened for recruitment
NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer
NCT05773859 · Phase 1/2 · Netherlands
Source: ClinicalTrials.govClosed for recruitment
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184 · Phase 1 · Australia, Belgium, Canada, Germany, Spain, France
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 1
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184 · Phase 1 · Australia, Belgium, Canada, Germany, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT05445778 · Phase 3 · Argentina, Australia, Belgium, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govPhase changed: Phase 4 → Phase 3
NCT05445778 · Phase 3 · Argentina, Australia, Belgium, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govClosed for recruitment
NCT05456685 · Phase 2 · Belgium, Canada, Spain, United Kingdom, Georgia, Ireland
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05257408 · Phase 3 · Argentina, Australia, Belgium, Brazil, Canada, Spain
Source: ClinicalTrials.govPhase changed: Phase 1 → Phase 1/2
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
NCT05198804 · Phase 1/2 · France, United States
Source: ClinicalTrials.govPhase changed: Phase 4 → Phase 3
NCT05116189 · Phase 3 · Australia, Belgium, Brazil, Canada, Chile, China
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05143970 · Phase 1 · Belgium, France
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133 · Phase 2 · Argentina, Bulgaria, China, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04625270 · Phase 2 · Belgium, Canada, Spain, France, United Kingdom, Italy
Source: ClinicalTrials.govOpened for recruitment
Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer
NCT04282356 · Phase 2 · France
Source: ClinicalTrials.govOpened for recruitment
NCT04300556 · Phase 1/2 · Spain, France, United Kingdom, Japan, United States
Source: ClinicalTrials.govClosed for recruitment
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963 · Phase 3 · Belgium, Bulgaria, Canada, China, Czechia, Germany
Source: ClinicalTrials.govClosed for recruitment
NCT03937154 · Phase 3 · Argentina, Brazil, Spain, Greece, Mexico, Peru
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04044859 · Phase 1 · Canada, Spain, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT03737643 · Phase 3 · Austria, Belgium, Bulgaria, Brazil, Canada, China
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT03522246 · Phase 3 · Australia, Belgium, Canada, Czechia, Germany, Denmark
Source: ClinicalTrials.govClosed for recruitment
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
NCT01376752 · Phase 3 · Belgium, Spain, France
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT02655016 · Phase 3 · Belgium, Switzerland, Czechia, Germany, Denmark, Spain
Source: ClinicalTrials.govClosed for recruitment
NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer
NCT05773859 · Phase 1/2 · Netherlands
Source: ClinicalTrials.govOpened for recruitment
NCT05456685 · Phase 2 · Belgium, Canada, Spain, United Kingdom, Georgia, Ireland
Source: ClinicalTrials.govOpened for recruitment
NCT05445778 · Phase 3 · Argentina, Australia, Belgium, Bulgaria, Brazil, Canada
Source: ClinicalTrials.govClosed for recruitment
NCT06161025 · Phase 2/3 · Australia, Brazil, Canada, China, Czechia, Germany
Source: ClinicalTrials.govOpened for recruitment
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184 · Phase 1 · Australia, Belgium, Canada, Germany, Spain, France
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer
NCT04282356 · Phase 2 · France
Source: ClinicalTrials.govOpened for recruitment
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
NCT01376752 · Phase 3 · Belgium, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT07736937 · Phase 1/2 · Belgium, Ukraine, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613 · Phase 1 · Spain, France, United Kingdom, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07340164 · Phase 2 · Spain, South Korea
Source: ClinicalTrials.govOpened for recruitment
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963 · Phase 3 · Belgium, Bulgaria, Canada, China, Czechia, Germany
Source: ClinicalTrials.govOpened for recruitment
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231 · Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govClosed for recruitment
NCT04300556 · Phase 1/2 · Spain, France, United Kingdom, Japan, United States
Source: ClinicalTrials.govOpened for recruitment
NCT03937154 · Phase 3 · Argentina, Brazil, Spain, Greece, Mexico, Peru
Source: ClinicalTrials.govOpened for recruitment
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185 · Phase 1 · Belgium, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089 · Phase 2 · Australia, China, Germany, Spain, France, Italy
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT06476808 · Phase 1 · Canada, Spain, France, Italy, United States
Source: ClinicalTrials.govNew in the registry
Peer Ambassador in Gyn Onc Trials
NCT07915336 · No phase · United States
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 1Ended 3 Nov 2026
Stopped early53 participants
NCT05075993
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Reason given: \<75% participation
Phase 2Ended 1 Nov 2026
Withdrawn before start0 participants
NCT05126342
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
Reason given: Study has been withdrawn; was never submitted to Competent authority nor to ethics commitee.
Phase 1Ended 26 Oct 2026
Stopped early19 participants
NCT05617755
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Reason given: Active patients have been rolled over to a separate LTFU study.
Phase 1Ended 15 Oct 2026
Stopped early3 participants
NCT07030907
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Reason given: Business decision
No phaseEnded 14 Oct 2026
Completed16 participants
NCT05440617
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Phase 1Ended 9 Oct 2026
Stopped early19 participants
NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Reason given: The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.
Phase 2Ended 28 Sept 2026
Completed17 participants
NCT06169124
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
- Androgen receptor as a therapeutic target in endometrial cancer: a narrative review. · International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2026
- A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor. · Gynecologic oncology, 2026
Phase 2Ended 24 Sept 2026
No phaseEnded 15 Sept 2026
No phaseEnded 1 Sept 2026
Phase 1Ended Aug 2026
Withdrawn before start0 participants
NCT04542603
Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer
Reason given: No recruitment/enrollment and funding expired.
No phaseEnded 28 Aug 2026
No phaseEnded 21 Aug 2026
Paused1000000 participants
NCT05506800
Guangzhou Women's Health Cohort Study (GWHCS)
Reason given: Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily.
Phase 2Ended 11 Aug 2026
Completed63 participants
NCT06433219
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
Phase 1/2Ended 31 Jul 2026
Stopped early20 participants
NCT03362606
Engineered Immune Effectors Against Ovarian Cancer
No reason given in the registry.
Phase 2Ended 31 Jul 2026
Completed50 participants
NCT04876456
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Phase 1/2Ended 31 Jul 2026
Stopped early100 participants
NCT03184753
Genetically Modified T Cells Against Ovarian Cancer
No reason given in the registry.
Phase 1Ended 16 Jul 2026
Completed138 participants
NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
No phaseEnded 16 Jul 2026
Withdrawn before start0 participants
NCT07226102
Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer
Reason given: slow accrual
Phase 1Ended 8 Jul 2026
Completed27 participants
NCT06399757
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Show more
No phaseEnded 1 Jul 2026
Completed401 participants
NCT06458361
Identification of Risk Factors and Construction of Prediction Model for Postoperative Intestinal Anastomotic Leakage in Ovarian Cancer
No phaseEnded 30 Jun 2026
Completed289 participants
NCT05130606
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Phase 1Ended 16 Jun 2026
Completed31 participants
NCT03586661
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1/2Ended 2 Jun 2026
Completed98 participants
NCT05864144
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 2Ended 1 Jun 2026
Completed22 participants
NCT04387227
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Early Phase 1Ended 31 May 2026
Withdrawn before start0 participants
NCT05238831
SMMART Adaptive Clinical Treatment (ACT) Trial
Reason given: Withdrawn due to a change in therapeutic interventions.
Phase 3Ended May 2026
Paused450 participants
NCT01218490
Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer
Reason given: qualitative analysis of the study database
Phase 1Ended 27 May 2026
Stopped early19 participants
NCT06466187
A Study of SGN-MesoC2 in Advanced Solid Tumors
Reason given: The trial was terminated for strategic reasons. The decision was not based on any safety concerns
No phaseEnded 19 May 2026
Phase 2Ended 8 May 2026
Completed50 participants
NCT05903807
68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian Cancer
Phase 2Ended 30 Apr 2026
Completed100 participants
2024-516629-30-00
Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS ≥1 positive ovarian, Fallopian tube and primary peritoneal cancer patients
Phase 1Ended 29 Apr 2026
Stopped early13 participants
NCT05057715
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Reason given: Sponsor decision
No phaseEnded 28 Apr 2026
Completed158 participants
NCT04862325
SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS
No phaseEnded 24 Apr 2026
Completed388 participants
NCT04295577
Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR
Phase 2Ended 21 Apr 2026
Completed62 participants
2023-505667-37-00
Sentinel node detection with 99Tc albumin nanocolloid and indocianine green (ICG) in patients with epithelial ovarian cancer in early stages. Pilot study.
No phaseEnded 16 Apr 2026
Completed126 participants
NCT04906187
Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery
Phase 3Ended 14 Apr 2026
No phaseEnded 1 Apr 2026
Stopped early24 participants
NCT07035067
Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada
Reason given: Recruitment
Phase 1Ended 1 Apr 2026
Completed94 participants
NCT04354246
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
No phaseEnded 31 Mar 2026
Completed926 participants
NCT04407611
Scalable Communication Modalities for Returning Genetic Research Results
No phaseEnded Mar 2026
Completed52 participants
NCT02109367
Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass
No phaseEnded 31 Mar 2026
Completed354 participants
NCT05021562
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
Phase 1Ended 31 Mar 2026
Completed47 participants
NCT05109975
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
No phaseEnded 30 Mar 2026
Stopped early5 participants
NCT07000344
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
Reason given: Results failed to achieve the anticipated effect.
No phaseEnded 27 Mar 2026
Completed755 participants
NCT04122235
The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study
Phase 1/2Ended 25 Mar 2026
Stopped early179 participants
NCT05180474
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Reason given: The Sponsor has made a strategic decision to stop the development of GEN1047.
No phaseEnded 23 Mar 2026
Completed72 participants
NCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
No phaseEnded 20 Mar 2026
No phaseEnded 18 Mar 2026
Completed25 participants
NCT05415527
Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management
No phaseEnded 17 Mar 2026
Completed140 participants
NCT06973161
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Phase 1Ended 17 Mar 2026
Stopped early85 participants
NCT05827614
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Reason given: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.
No phaseEnded 12 Mar 2026
Phase 2Ended 11 Mar 2026
Stopped early6 participants
NCT06630325
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Reason given: Loss of support.
Phase 1Ended 6 Mar 2026
Stopped early1 participant
NCT05397093
ITIL-306 in Advanced Solid Tumors
Reason given: The study was terminated early due to discontinuation of development of the investigational program
No phaseEnded 28 Feb 2026
Completed1 participant
NCT07651020
The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors
No phaseEnded 21 Feb 2026
Completed60 participants
NCT07241091
SurgiPerito Trial: High-Purity Type-I Collagen for Peritoneal Reconstruction After Cytoreductive Surgery
No phaseEnded 14 Feb 2026
Completed568 participants
NCT06624878
Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer
Phase 2Ended 12 Feb 2026
Phase 2Ended 1 Feb 2026
Withdrawn before start0 participants
NCT05736952
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
Reason given: Program changed
Phase 2Ended 1 Feb 2026
Stopped early29 participants
NCT06760702
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers
Reason given: Patient recruitment problems.
Not medical advice. fetched 11 Nov 2026